Bessemer Group
BVS icon

Bessemer Group’s Bioventus BVS Stock Holding History

Bessemer Group’s Portfolio BVS Stock Details BVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
4
– – ﹤0.01% 2501
2025
Q4 		$0 Hold
4
– – ﹤0.01% 2540
2025
Q3 		$0 Hold
4
– – ﹤0.01% 2500
2025
Q2 		$0 Hold
4
– – ﹤0.01% 2411
2025
Q1 		$0 Hold
4
– – ﹤0.01% 2463
2024
Q4 		$0 Buy
+4
New +$47 ﹤0.01% 2479

Other funds holding BVS

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
JIC
Juniper Investment Company New York $313M AUM 79.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bessemer Group's BVS Position: Q1 2026 in Review

Bessemer Group held its Bioventus (BVS) position steady in Q1 2026 at 4 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2501.

Bessemer Group first reported a position in BVS in Q4 2024 and has held it in 6 quarters since. 157 funds tracked by Wall St. Rank hold BVS as of Q1 2026.

  • Bessemer Group held 4 shares of Bioventus worth $0 as of Q1 2026.
  • Bessemer Group left its Bioventus share count unchanged in Q1 2026.
  • Bioventus made up ﹤0.01% of Bessemer Group's portfolio in Q1 2026, its #2501 holding.
  • Bessemer Group first reported a position in Bioventus in Q4 2024 and has held it in 6 quarters since.
  • 157 funds tracked by Wall St. Rank held Bioventus as of Q1 2026.

Based on Bessemer Group's 13F filing for Q1 2026, filed 6 May 2026.